- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on Relapsed or Refractory EBV-and CD30-positive Lymphomas
Total 929 results
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterCompletedRelapsed or Refractory EBV-and CD30-positive LymphomasKorea, Republic of
-
The First Affiliated Hospital of Soochow UniversityShanghai Unicar-Therapy Bio-medicine Technology Co.,LtdUnknownRefractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | CAR - T CD19/CD20/CD22/CD30China
-
Eric Bernicker, MDMillennium Pharmaceuticals, Inc.; The Methodist Hospital Research InstituteWithdrawnCD30-positive Lymphoma | CD30-positive Solid TumorUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedCD30-Positive Diffuse Large B-Cell Lymphoma | CD30 Positive Primary Mediastinal Large B-cell Lymphoma | CD30-Positive Gray Zone LymphomaUnited States
-
Fujian Medical UniversityRecruitingRelapsed or Refractory DLBCL Patients With Either CD19 or CD20 PositiveChina
-
The Affiliated Hospital of the Chinese Academy...Chinese PLA General HospitalUnknown
-
TakedaCompletedRelapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell LymphomaJapan
-
Viracta Therapeutics, Inc.RecruitingEBV Related Non-Hodgkin's Lymphoma | Epstein-Barr Virus Associated Lymphoproliferative Disorder | EBV-Related PTLD | EBV Associated Lymphoma | EBV-Positive DLBCL, NOS | EBV Related PTCL, NOSUnited States, Spain, Italy, United Kingdom, Singapore, Taiwan, Korea, Republic of, Malaysia, Germany, Canada, Brazil, Australia, France, Hong Kong, Israel
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | CCND1 Positive | CCND2 Positive | CCND3 Positive | CD20 Positive | Refractory Mantle Cell LymphomaUnited States
-
Medical College of WisconsinMidwest Athletes Against Childhood CancerNot yet recruitingLymphoma | Leukemia | Hodgkin Disease | CD30-Positive Diffuse Large B-Cell Lymphoma | CD30+ Anaplastic Large Cell Lymphoma | CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma | CD30+ Immunoblastic Large T-Cell Cutaneous LymphomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRecurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditionsUnited States
-
Baylor College of MedicineThe Methodist Hospital Research InstituteRecruitingEBV-Related Hodgkin Lymphoma | EBV Related Non-Hodgkin's Lymphoma | EBV-Related Lymphoproliferative DisorderUnited States
-
University of CologneUnknownCD30 Positive Cutaneous T Cell Lymphoma | CD30 Positive Transformed Mycosis FungoidesGermany
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalNot yet recruitingCD19-positive Relapsed or Refractory B-cell MalignanciesChina
-
Poitiers University HospitalCompleted
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...CompletedLymphoproliferative Disorders | Hodgkin Lymphoma | EBV Related Non-Hodgkin's Lymphoma | NonHodgkin Lymphoma | EBV-Related PTLD | EBV Related Lymphoma | EBV Related Hodgkin's LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | CD20 Positive | Refractory Mantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | CCND1 Protein Overexpression | CD5 Positive | FCER2 Negative | Pleomorphic Variant Mantle Cell Lymphoma | t(11;14)(q13;q32)United States
-
National Cancer Institute (NCI)CompletedRefractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | CD20 PositiveUnited States
-
Xin WangUnknownRelapsed or Refractory B-cell LymphomasChina
-
Curis, Inc.The Leukemia and Lymphoma SocietyCompletedLymphoma | Refractory Lymphoma | Relapsed Lymphoma | Relapsed and/or Refractory Lymphoma | Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL) | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Double-hit Lymphoma (DHL) | Triple-hit Lymphoma... and other conditionsUnited States
-
TakedaCompletedUntreated CD30-Positive Hodgkin's LymphomaJapan
-
National Cancer Institute (NCI)Active, not recruitingPlasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterParker Institute for Cancer ImmunotherapyRecruitingRecurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditionsUnited States
-
Bristol-Myers SquibbRecruitingRelapsed or Refractory T-cell LymphomasJapan
-
Memorial Sloan Kettering Cancer CenterUniversity of NebraskaCompletedT-cell Lymphomas | Relapsed or RefractoryUnited States
-
Hoffmann-La RocheCompletedRelapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell LymphomaUnited States, Spain, United Kingdom
-
Lantern Pharma Inc.RecruitingAdvanced Solid Tumor | Relapsed or Refractory LymphomasUnited States
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnAnaplastic Large Cell Lymphoma, ALK-Positive | CD30-Positive Neoplastic Cells Present | Systemic Anaplastic Large Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 PositiveUnited States
-
Allogene TherapeuticsRecruitingRelapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaUnited States, Spain, Canada, Australia, Italy
-
Millennium Pharmaceuticals, Inc.CompletedRelapsed or Refractory Hodgkin Lymphoma | Relapsed or Refractory Anaplastic Large-cell LymphomaUnited States, France, United Kingdom, Germany, Spain, Netherlands, Italy, Mexico
-
University Health Network, TorontoTakara Bio Inc.RecruitingRelapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell LymphomaCanada
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRelapsed or Refractory Lymphoma or Advanced CancerChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Tayu Huaxia Biotech Medical Group Co., Ltd.RecruitingLocally Advanced /Metastatic Solid Tumors | Relapsed or Refractory LymphomasChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnMantle Cell Lymphoma | CCND1 Positive | CD20-Positive Neoplastic Cells Present
-
HutchmedCompleted
-
Yale UniversityMerck Sharp & Dohme LLCTerminatedRelapsed Lymphomas | Refractory LymphomasUnited States
-
AstraZenecaActive, not recruitingPhase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic LeukemiaChina
-
HutchmedCompleted
-
City of Hope Medical CenterWithdrawnSezary Syndrome | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Folliculotropic Mycosis Fungoides | CD30-Positive Neoplastic Cells Present | Refractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaUnited States
-
HutchmedCompletedRelapsed or Refractory LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Lymphoma | CD20 Positive | Lymphocytic NeoplasmUnited States
-
Han weidongRecruitingRelapsed and Refractory B-cell Non-Hodgkin's Lymphoma | Decitabine-primed Tandem CD19/CD20 CAR T CellsChina
-
Ruijin HospitalRecruitingPrimary Mediastinal Large B Cell Lymphoma | EBV-Positive DLBCL, NosChina
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...RecruitingRefractory or Recurrent CD30+ Hematologic MalignanciesChina
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.; Janssen Biotech, Inc.RecruitingAdult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)United States
-
Guangzhou Excelmab Inc.RecruitingSafety and Efficacy of EX103 in Subjects With Relapsed/Refractory CD20-Positive Non-Hodgkin LymphomaCD20-positive Non-Hodgkin LymphomaChina
-
Conjupro Biotherapeutics, Inc.SuspendedCD20 Positive Non Hodgkin LymphomaUnited States